USA flag logo/image

An Official Website of the United States Government

SBIR Phase I: High Throughput Screening of Multivalent Drugs and Nanomedicine

Award Information

Agency:
National Science Foundation
Branch:
N/A
Award ID:
88398
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
0810474
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
MICROSURFACES INC
3913 Todd Lane SUITE 102 Austin, TX 78744-
View profile »
Woman-Owned: Yes
Minority-Owned: Yes
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: SBIR Phase I: High Throughput Screening of Multivalent Drugs and Nanomedicine
Agency: NSF
Contract: 0810474
Award Amount: $100,000.00
 

Abstract:

This Small Business Innovation Research Phase I project develops cell membrane mimetic-microarrays for high-throughput screening and analysis of multivalent drug candidates, particularly nanomedicine. Traditional drugs based on mono-valent and high-affinity interactions can lead to non-specific side effects and toxicity. Advances in synthetic and processing techniques for nanoparticles (inorganic, organic, dendrimer, polymer, liposomes, and etc.) have made available an increasing library of drug candidates that incorporate multivalent surface functionalities for targeting specific cells. The proposed cell membrane mimicking microarrays will be based on an air-stable and fluidic supported lipid bilayer system; the robustness of the proposed membrane microarrays greatly simplifies manufacturing, product distribution, and usage. This product will be of high value to pharmaceutical companies and research institutions that are involved in multivalent and nanomedicine development as well as fundamental research on cell-cell interactions. The broader impacts of this research are contributions to drug development and human health. Nanomedicine is a $7 billion market today and growing at double digits annually. While pharmaceutical companies, biotech startups, and academic laboratories are actively developing nanoparticle-based therapies, there are no products that provide high-throughput analysis of these potential drug candidates. The proposed research will allow development of a superior product to meet the needs for large-scale screening of multivalent drug candidates and, in return, accelerate the development of nanomedicine.

Principal Investigator:

Athena Guo
PhD
6127890104
athena@memsurface.com

Business Contact:

Athena Guo
PhD
6127890104
athena@memsurface.com
Small Business Information at Submission:

MICROSURFACES INC
4001 STINSON BLVD SUITE 430 MINNEAPOLIS, MN 55421

EIN/Tax ID: 411974237
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No